1. Prognostic factors of non-ampullary duodenal adenocarcinoma
   Teijiro Hirashita et al, 2018, Japanese Journal of Clinical Oncology CrossRef
2. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study
   Laura M. Legué et al, 2019, Targeted Oncology CrossRef
3. Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
   Takahiro Amano et al, 2021, BMC Cancer CrossRef
4. Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives
   Emilie Moati et al, 2022, Cancers CrossRef
5. Evaluation of Systemic Treatments of Small Intestinal Adenocarcinomas
   Tim de Back et al, 2023, JAMA Network Open CrossRef
6. Enhancing treatment strategies for small bowel cancer: a clinical review of targeted therapy and immunotherapy approaches
   Mehrshad Ebrahimpour et al, 2024, Naunyn-Schmiedeberg's Archives of Pharmacology CrossRef
7. Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis
   John Paulo Vergara et al, 2019, Rare Tumors CrossRef
8. Clinical practice guidelines for duodenal cancer 2021
   Kenji Nakagawa et al, 2022, Journal of Gastroenterology CrossRef
9. Characteristics and outcome of patients with small bowel adenocarcinoma (SBA)
   Andreas Teufel et al, 2023, Journal of Cancer Research and Clinical Oncology CrossRef